In patients with advanced NSCLC (n = 43), Constantini et al. similarly found that patients with low sPD-L1 levels (< 33.97 pg/ml) had a longer PFS (p = 0.018) and a trend of longer OS (p = 0.096) following treatment with nivolumab than patients with high levels [36]. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.